{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:15:15Z","timestamp":1790882115037,"version":"4.1.0"},"reference-count":83,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["NCT02649231"],"award-info":[{"award-number":["NCT02649231"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Behavioural Brain Research"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.bbr.2020.112629","type":"journal-article","created":{"date-parts":[[2020,5,30]],"date-time":"2020-05-30T19:35:22Z","timestamp":1590867322000},"page":"112629","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"special_numbering":"C","title":["Ketamine as a mental health treatment: Are acute psychoactive effects associated with outcomes? A systematic review"],"prefix":"10.1016","volume":"392","author":[{"given":"Meryem","family":"Grabski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Borissova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Marsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia J.A.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.Valerie","family":"Curran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.bbr.2020.112629_bib0005","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1177\/0269881117705089","article-title":"Ketamine\u2019s dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders","volume":"31","author":"Glue","year":"2017","journal-title":"J. Psychopharmacol."},{"issue":"12","key":"10.1016\/j.bbr.2020.112629_bib0010","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1038\/npp.2013.150","article-title":"Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept","volume":"38","author":"Rodriguez","year":"2013","journal-title":"Neuropsychopharmacology."},{"key":"10.1016\/j.bbr.2020.112629_bib0015","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2018.00277","article-title":"Efficacy of ketamine in the treatment of substance use disorders: a systematic review","volume":"9","author":"Jones","year":"2018","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.bbr.2020.112629_bib0020","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.neuropharm.2018.01.017","article-title":"Ketamine for the treatment of addiction: evidence and potential mechanisms","volume":"142","author":"Ezquerra-Romano","year":"2018","journal-title":"J. Neuropharmacol."},{"issue":"44","key":"10.1016\/j.bbr.2020.112629_bib0025","doi-asserted-by":"crossref","first-page":"11158","DOI":"10.1523\/JNEUROSCI.1547-16.2016","article-title":"Ketamine: NMDA receptors and beyond","volume":"36","author":"Zorumski","year":"2016","journal-title":"J. Neurosci."},{"issue":"1","key":"10.1016\/j.bbr.2020.112629_bib0030","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.neuropharm.2011.07.036","article-title":"Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders","volume":"62","author":"Sanacora","year":"2012","journal-title":"Neuropharmacology."},{"key":"10.1016\/j.bbr.2020.112629_bib0035","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jad.2014.02.017","article-title":"Do the dissociative side effects of ketamine mediate its antidepressant effects?","volume":"159","author":"Luckenbaugh","year":"2014","journal-title":"J. Affect. Disord."},{"issue":"3","key":"10.1016\/j.bbr.2020.112629_bib0040","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/archpsyc.1994.03950030035004","article-title":"Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses","volume":"51","author":"Krystal","year":"1994","journal-title":"Arch. Gen. Psychiatry"},{"issue":"4","key":"10.1016\/j.bbr.2020.112629_bib0045","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1177\/0269881113512909","article-title":"Reviewing the ketamine model for schizophrenia","volume":"28","author":"Frohlich","year":"2014","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.bbr.2020.112629_bib0050","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/00005053-196312000-00007","article-title":"Reactions to psilocybin administered in a supportive environment","volume":"137","author":"Leary","year":"1963","journal-title":"J. Nerv. Ment. Dis."},{"issue":"12","key":"10.1016\/j.bbr.2020.112629_bib0055","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.bbr.2020.112629_bib0060","doi-asserted-by":"crossref","first-page":"974","DOI":"10.3389\/fphar.2017.00974","article-title":"Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression","volume":"8","author":"Roseman","year":"2017","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.bbr.2020.112629_bib0065","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2174\/1874473708666150107121331","article-title":"Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction","volume":"7","author":"Garcia-Romeu","year":"2014","journal-title":"Curr. Drug Abuse Rev."},{"key":"10.1016\/j.bbr.2020.112629_bib0070","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.neuropharm.2018.01.005","article-title":"A sub-set of psychoactive effects may be critical to the behavioral impact of ketamine on cocaine use disorder: results from a randomized, controlled laboratory study","volume":"142","author":"Dakwar","year":"2018","journal-title":"J. Neuropharmacol."},{"issue":"5994","key":"10.1016\/j.bbr.2020.112629_bib0075","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1126\/science.1190287","article-title":"mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists","volume":"329","author":"Li","year":"2010","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.bbr.2020.112629_bib0080","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/JCP.0b013e31825d70d6","article-title":"A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder","volume":"32","author":"Ibrahim","year":"2012","journal-title":"J. Clin. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.bbr.2020.112629_bib0085","doi-asserted-by":"crossref","first-page":"247","DOI":"10.4088\/JCP.13m08852","article-title":"Ketamine safety and tolerability in clinical trials for treatment-resistant depression","volume":"76","author":"Wan","year":"2015","journal-title":"J. Clin. Psychiatry"},{"issue":"4","key":"10.1016\/j.bbr.2020.112629_bib0090","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.biopsych.2012.06.022","article-title":"Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression","volume":"74","author":"Murrough","year":"2013","journal-title":"Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.bbr.2020.112629_bib0095","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00213-013-3255-x","article-title":"Neurocognitive effects of ketamine in treatment-resistant major depression: association with antidepressant response","volume":"231","author":"Murrough","year":"2014","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.bbr.2020.112629_bib0100","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1017\/S1461145709000169","article-title":"Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial","volume":"13","author":"Mathew","year":"2010","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"4","key":"10.1016\/j.bbr.2020.112629_bib0105","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/da.22253","article-title":"Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression","volume":"31","author":"Price","year":"2014","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.bbr.2020.112629_bib0110","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.jad.2018.02.049","article-title":"Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression","volume":"232","author":"Niciu","year":"2018","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.bbr.2020.112629_bib0115","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jad.2016.10.026","article-title":"Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion","volume":"208","author":"Pennybaker","year":"2017","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.bbr.2020.112629_bib0120","series-title":"Do the Dissociative Side Effects of Ketamine Mediate Its Antidepressant Effects?","first-page":"56","author":"Luckenbaugh","year":"2014"},{"issue":"2","key":"10.1016\/j.bbr.2020.112629_bib0125","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1017\/S1461145712000545","article-title":"Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder","volume":"16","author":"Duncan","year":"2012","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"8","key":"10.1016\/j.bbr.2020.112629_bib0130","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1001\/archgenpsychiatry.2010.90","article-title":"A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression","volume":"67","author":"Diazgranados","year":"2010","journal-title":"Arch. Gen. Psychiatry"},{"issue":"8","key":"10.1016\/j.bbr.2020.112629_bib0135","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression","volume":"63","author":"Zarate","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"issue":"12","key":"10.1016\/j.bbr.2020.112629_bib0140","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.biopsych.2013.02.008","article-title":"Neural correlates of rapid antidepressant response to ketamine in treatment-resistant unipolar depression: a preliminary positron emission tomography study","volume":"73","author":"Carlson","year":"2013","journal-title":"Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.bbr.2020.112629_bib0145","doi-asserted-by":"crossref","first-page":"247","DOI":"10.4088\/JCP.13m08852","article-title":"Ketamine safety and tolerability in clinical trials for treatment-resistant depression","volume":"76","author":"Wan","year":"2015","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.bbr.2020.112629_bib0150","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.jad.2018.02.049","article-title":"Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression","volume":"232","author":"Niciu","year":"2018","journal-title":"J. Affect. Disord."},{"issue":"4","key":"10.1016\/j.bbr.2020.112629_bib0155","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.euroneuro.2019.02.005","article-title":"Anxiety during ketamine infusions is associated with negative treatment responses in major depressive disorder","volume":"29","author":"Aust","year":"2019","journal-title":"J. Eur. Neuropsychopharmacol."},{"issue":"6","key":"10.1016\/j.bbr.2020.112629_bib0160","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.15m10056","article-title":"Rapid and sustained reductions in current suicidal ideation following repeated doses of intravenous ketamine: secondary analysis of an open-label study","volume":"77","author":"Ionescu","year":"2016","journal-title":"J. Clin. Psychiatry"},{"issue":"2","key":"10.1016\/j.bbr.2020.112629_bib0165","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00213-014-3669-0","article-title":"D-serine plasma concentration is a potential biomarker of (R, S)-ketamine antidepressant response in subjects with treatment-resistant depression","volume":"232","author":"Moaddel","year":"2015","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.bbr.2020.112629_bib0170","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jad.2013.10.036","article-title":"Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression","volume":"155","author":"Shiroma","year":"2014","journal-title":"J. Affect. Disord."},{"issue":"6","key":"10.1016\/j.bbr.2020.112629_bib0175","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1097\/JCP.0000000000000960","article-title":"Efficacy and safety of a rapid intravenous injection of ketamine 0.5 mg\/kg in treatment-resistant major depression: an open 4-Week longitudinal study","volume":"38","author":"Vidal","year":"2018","journal-title":"J. Clin. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.bbr.2020.112629_bib0180","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.17m11731","article-title":"Acute and longer-term outcomes using ketamine as a clinical treatment at the yale psychiatric hospital","volume":"79","author":"Wilkinson","year":"2018","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.bbr.2020.112629_bib0185","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jpsychires.2018.09.013","article-title":"Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression","volume":"106","author":"Zheng","year":"2018","journal-title":"J. Psychiatr. Res."},{"issue":"4","key":"10.1016\/j.bbr.2020.112629_bib0190","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biol. Psychiatry"},{"issue":"4","key":"10.1016\/j.bbr.2020.112629_bib0195","first-page":"287","article-title":"Relationship of ketamine\u2019s antidepressant and psychotomimetic effects in unipolar depression","volume":"34","author":"Sos","year":"2013","journal-title":"Neuroendocrinol Lett."},{"issue":"2","key":"10.1016\/j.bbr.2020.112629_bib0200","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.pscychresns.2010.10.009","article-title":"The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [1H]-MRS","volume":"191","author":"Valentine","year":"2011","journal-title":"Psychiatry Res. Neuroimaging"},{"issue":"12","key":"10.1016\/j.bbr.2020.112629_bib0205","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.biopsych.2014.03.026","article-title":"A randomized controlled trial of intranasal ketamine in major depressive disorder","volume":"76","author":"Lapidus","year":"2014","journal-title":"Biol. Psychiatry"},{"issue":"5","key":"10.1016\/j.bbr.2020.112629_bib0210","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1176\/appi.ajp.2018.18070834","article-title":"Single, repeated, and maintenance ketamine infusions for treatment-resistant depression: a randomized controlled trial","volume":"176","author":"Phillips","year":"2019","journal-title":"Am. J. Psychiatry"},{"issue":"12","key":"10.1016\/j.bbr.2020.112629_bib0215","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1176\/appi.ajp.2018.18020138","article-title":"Attenuation of antidepressant effects of ketamine by opioid receptor antagonism","volume":"175","author":"Williams","year":"2018","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.bbr.2020.112629_bib0220","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.pscychresns.2010.10.009","article-title":"The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [1H]-MRS","volume":"191","author":"Valentine","year":"2011","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.bbr.2020.112629_bib0225","first-page":"1","article-title":"Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD)","author":"Fava","year":"2018","journal-title":"J. Mol. Psychiatry"},{"issue":"6","key":"10.1016\/j.bbr.2020.112629_bib0230","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1176\/appi.ajp.2019.19020172","article-title":"Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study","volume":"176","author":"Popova","year":"2019","journal-title":"Am. J. Psychiatry"},{"issue":"6","key":"10.1016\/j.bbr.2020.112629_bib0235","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1097\/JCP.0000000000000960","article-title":"Efficacy and safety of a rapid intravenous injection of ketamine 0.5 mg\/kg in treatment-resistant major depression: An open 4-week longitudinal study","volume":"38","author":"Vidal","year":"2018","journal-title":"J. Clin. Psychopharmacol."},{"issue":"6","key":"10.1016\/j.bbr.2020.112629_bib0240","first-page":"428","article-title":"Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study","volume":"176","author":"Popova","year":"2019","journal-title":"J. Clin. Psychopharmacol."},{"issue":"12","key":"10.1016\/j.bbr.2020.112629_bib0245","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.biopsych.2014.03.026","article-title":"A randomized controlled trial of intranasal ketamine in major depressive disorder","volume":"76","author":"Lapidus","year":"2014","journal-title":"Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.bbr.2020.112629_bib0250","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00213-014-3669-0","article-title":"D-serine plasma concentration is a potential biomarker of (R, S)-ketamine antidepressant response in subjects with treatment-resistant depression","volume":"232","author":"Moaddel","year":"2015","journal-title":"Psychopharmacology (Berl.)"},{"issue":"5","key":"10.1016\/j.bbr.2020.112629_bib0255","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1176\/appi.ajp.2018.18070834","article-title":"Single, repeated, and maintenance ketamine Infusions for treatment-resistant depression: a randomized controlled trial","volume":"176","author":"Phillips","year":"2019","journal-title":"Am. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.bbr.2020.112629_bib0260","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bbr.2020.112629_bib0265","first-page":"1","article-title":"Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD)","author":"Fava","year":"2018","journal-title":"Mol. Psychiatry"},{"issue":"4","key":"10.1016\/j.bbr.2020.112629_bib0270","first-page":"287","article-title":"Relationship of ketamine\u2019s antidepressant and psychotomimetic effects in unipolar depression","volume":"34","author":"Sos","year":"2013","journal-title":"Neuroendocrinol Lett"},{"issue":"4","key":"10.1016\/j.bbr.2020.112629_bib0275","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.17m11731","article-title":"Acute and longer-term outcomes using ketamine as a clinical treatment at the yale psychiatric hospital","volume":"79","author":"Wilkinson","year":"2018","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.bbr.2020.112629_bib0280","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jad.2013.10.036","article-title":"Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression","volume":"155","author":"Shiroma","year":"2014","journal-title":"J. Affect. Disord."},{"issue":"12","key":"10.1016\/j.bbr.2020.112629_bib0285","first-page":"1205","article-title":"Attenuation of antidepressant effects of ketamine by opioid receptor antagonism","volume":"175","author":"Williams","year":"2018","journal-title":"Mol. Psychiatry"},{"issue":"4","key":"10.1016\/j.bbr.2020.112629_bib0290","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.euroneuro.2019.02.005","article-title":"Anxiety during ketamine infusions is associated with negative treatment responses in major depressive disorder","volume":"29","author":"Aust","year":"2019","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"6","key":"10.1016\/j.bbr.2020.112629_bib0295","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.15m10056","article-title":"Rapid and sustained reductions in current suicidal ideation following repeated doses of intravenous ketamine","volume":"77","author":"Ionescu","year":"2016","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.bbr.2020.112629_bib0300","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jpsychires.2018.09.013","article-title":"Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression","volume":"106","author":"Zheng","year":"2018","journal-title":"J. Psychiatr. Res."},{"issue":"1","key":"10.1016\/j.bbr.2020.112629_bib0305","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1023\/A:1024465317902","article-title":"Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS)","volume":"11","author":"Bremner","year":"1998","journal-title":"J. Trauma. Stress"},{"issue":"1","key":"10.1016\/j.bbr.2020.112629_bib0310","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression. Journal of neurology, neurosurgery, and psychiatry","volume":"23","author":"Hamilton","year":"1960","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"12","key":"10.1016\/j.bbr.2020.112629_bib0315","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.biopsych.2013.02.008","article-title":"Neural correlates of rapid antidepressant response to ketamine in treatment-resistant unipolar depression: a preliminary positron emission tomography study","volume":"73","author":"Carlson","year":"2013","journal-title":"Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.bbr.2020.112629_bib0320","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.bbr.2020.112629_bib0325","series-title":"Columbia-suicide Severity Rating Scale (C-SSRS)","author":"Posner","year":"2008"},{"issue":"3","key":"10.1016\/j.bbr.2020.112629_bib0330","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The brief psychiatric rating scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychol. Rep."},{"key":"10.1016\/j.bbr.2020.112629_bib0335","series-title":"5D-ABZ: Fragebogen Zur Erfassung Aussergew\u00f6hnlicher Bewusstseinszust\u00e4nde","author":"Dittrich","year":"1999"},{"key":"10.1016\/j.bbr.2020.112629_bib0340","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.neuropharm.2018.01.005","article-title":"A sub-set of psychoactive effects may be critical to the behavioral impact of ketamine on cocaine use disorder: results from a randomized, controlled laboratory study","volume":"142","author":"Dakwar","year":"2018","journal-title":"Neuropharmacology."},{"key":"10.1016\/j.bbr.2020.112629_bib0345","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.drugalcdep.2013.12.019","article-title":"Therapeutic infusions of ketamine: do the psychoactive effects matter?","volume":"136","author":"Dakwar","year":"2014","journal-title":"J. Drug and Alcohol Dependence."},{"issue":"2","key":"10.1016\/j.bbr.2020.112629_bib0350","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1080\/02791072.1997.10400185","article-title":"Ketamine psychedelic therapy (KPT): a review of the results of ten years of research","volume":"29","author":"Krupitsky","year":"1997","journal-title":"J. Psychoactive Drugs"},{"key":"10.1016\/j.bbr.2020.112629_bib0355","series-title":"Ketamine Psychedelic Therapy (KPT): a Review of the Results of Ten Years of Research","first-page":"165","author":"Krupitsky","year":"1997"},{"key":"10.1016\/j.bbr.2020.112629_bib0360","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.drugalcdep.2013.12.019","article-title":"Therapeutic infusions of ketamine: do the psychoactive effects matter?","volume":"136","author":"Dakwar","year":"2014","journal-title":"Drug Alcohol Depend."},{"issue":"2","key":"10.1016\/j.bbr.2020.112629_bib0365","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/npp.2017.194","article-title":"Ketamine for social anxiety disorder: a randomized, placebo-controlled crossover trial","volume":"43","author":"Taylor","year":"2018","journal-title":"Neuropsychopharmacology."},{"issue":"1","key":"10.1016\/j.bbr.2020.112629_bib0370","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1023\/A:1024465317902","article-title":"Measurement of dissociative states with the clinician\u2010administered dissociative states scale (CADSS)","volume":"11","author":"Bremner","year":"1998","journal-title":"J. Trauma. Stress"},{"key":"10.1016\/j.bbr.2020.112629_bib0375","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jad.2017.09.023","article-title":"Acute psychoactive effects of intravenous ketamine during treatment of mood disorders: analysis of the Clinician administered Dissociative State Scale","volume":"227","author":"van Schalkwyk","year":"2018","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.bbr.2020.112629_bib0380","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jad.2017.11.088","article-title":"Dissociation after ketamine dosing: Is the CADSS fit for purpose?","volume":"244","author":"Neehoff","year":"2019","journal-title":"J. Affect. Disord."},{"issue":"10","key":"10.1016\/j.bbr.2020.112629_bib0385","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1177\/0269881117725685","article-title":"Effect of ketamine dose on self-rated dissociation in patients with treatment refractory anxiety disorders","volume":"31","author":"Castle","year":"2017","journal-title":"J. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.bbr.2020.112629_bib0390","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/npp.2017.194","article-title":"Ketamine for social anxiety disorder: a randomized, placebo-controlled crossover trial","volume":"43","author":"Taylor","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bbr.2020.112629_bib0395","series-title":"The Brief Psychiatric Rating Scale","first-page":"799","author":"Overall","year":"1962"},{"key":"10.1016\/j.bbr.2020.112629_bib0400","series-title":"Reviewing the Ketamine Model for Schizophrenia","first-page":"287","author":"Frohlich","year":"2014"},{"issue":"1-3","key":"10.1016\/j.bbr.2020.112629_bib0405","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.schres.2008.02.020","article-title":"The psychotomimetic states inventory (PSI): measuring psychotic-type experiences from ketamine and cannabis","volume":"103","author":"Mason","year":"2008","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bbr.2020.112629_bib0410","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jad.2017.09.023","article-title":"Acute psychoactive effects of intravenous ketamine during treatment of mood disorders: analysis of the Clinician administered Dissociative State Scale","volume":"227","author":"van Schalkwyk","year":"2018","journal-title":"J. Affect. Disord."},{"issue":"6","key":"10.1016\/j.bbr.2020.112629_bib0415","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/00005053-198306000-00007","article-title":"The near-death experience scale. Construction, reliability, and validity","volume":"171","author":"Greyson","year":"1983","journal-title":"J. Nerv. Mental Dis."}],"container-title":["Behavioural Brain Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166432820303284?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166432820303284?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T21:16:24Z","timestamp":1777497384000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166432820303284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":83,"alternative-id":["S0166432820303284"],"URL":"https:\/\/doi.org\/10.1016\/j.bbr.2020.112629","relation":{},"ISSN":["0166-4328"],"issn-type":[{"value":"0166-4328","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ketamine as a mental health treatment: Are acute psychoactive effects associated with outcomes? A systematic review","name":"articletitle","label":"Article Title"},{"value":"Behavioural Brain Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbr.2020.112629","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"112629"}}